HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

VESALIUS-CV: Repatha cut first heart attack or stroke 25% in high-risk primary prevention

Gokhan Can · Nov 08, 2025 · ♥ 13 reactions · 3 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panelHeart attack, stroke & procedures
AI summary & key facts

Summarises VESALIUS-CV in 12,000+ high-risk patients without prior MI or stroke (median age 66, LDL-C >=90 mg/dL on therapy). Adding evolocumab cut 3-point MACE 25% over ~4.5 years, with LDL-C reduced about 55% to a median 45 mg/dL versus 109 mg/dL on placebo.

Repatha Cuts Risk of First Heart Attack or Stroke by 25% in High-Risk Patients

The VESALIUS-CV trial focused on a specific high-risk primary prevention population of over 12,000 patients (median age 66) who had not yet experienced a heart attack or stroke. These individuals were enrolled because they had established atherosclerosis or high-risk diabetes, and all had an LDL-C level of at least 90 mg/dL (median baseline of ~115-122 mg/dL) despite being on other lipid-lowering therapies. The trial demonstrated that adding evolocumab (Repatha) to their treatment significantly reduced the risk of a first major adverse cardiovascular event (MACE). Over a median follow-up of approximately 4.5 years, evolocumab cut the risk of the primary 3-point MACE by 25% compared to placebo (a composite of coronary heart disease death, heart attack, or ischemic stroke). This benefit was driven by a significant reduction in cholesterol, with the evolocumab group lowering LDL-C by nearly 55% to a median level of 45 mg/dL (vs 109mg/dL in controls).

References:

Paper · N Engl J Med · 2026Evolocumab in Patients without a Previous Myocardial Infarction or StrokeThe proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, s...nejm.org

Research cited

#repatha#cardiovascular#cardiology#nejm#heartattack#stroke#prevention#heartdisease
← newer: Merck oral PCSK9 pill called a likely game changerolder: Cystatin C blood test may flag kidney and heart risk that cr →